Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety of Repeated Topical Application of Three Concentrations of NF-kappaB Decoy in Adults With Mild-to-Moderate Atopic Dermatitis

NCT00125333 is registered in ClinicalTrials.gov with Anesiva, Inc. as lead sponsor.

NCT NCT00125333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00125333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety of Repeated Topical Application of Three Concentrations of NF-kappaB Decoy in Adults With Mild-to-Moderate Atopic Dermatitis
Lead sponsor
Anesiva, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2005
Completion date
November 30, 2005
Enrollment
75
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis